[1]程德军,黄斌,李明田.N-烯丙基-N-(1-(5-溴-2-((4-氯苄基)氧基)苄基)-4-哌啶基)吡啶甲酰胺的合成及表征[J].江西师范大学学报(自然科学版),2014,(04):346-349.
 CHENG De-jun,HUANG Bin,LI Ming-tian.The Synthesis and Structural Characterization of N-Allyl-N-(1-(5-Brono-2-((4-Chlorobenzyl)Oxy)Benzyl)PiPeridin-4-Yl)Picolinanide[J].,2014,(04):346-349.
点击复制

N-烯丙基-N-(1-(5-溴-2-((4-氯苄基)氧基)苄基)-4-哌啶基)吡啶甲酰胺的合成及表征()
分享到:

《江西师范大学学报》(自然科学版)[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2014年04期
页码:
346-349
栏目:
出版日期:
2014-08-31

文章信息/Info

Title:
The Synthesis and Structural Characterization of N-Allyl-N-(1-(5-Brono-2-((4-Chlorobenzyl)Oxy)Benzyl)PiPeridin-4-Yl)Picolinanide
作者:
程德军;黄斌;李明田
四川理工学院材料与化学工程学院,四川 自贡,643000
Author(s):
CHENG De-jun;HUANG Bin;LI Ming-tian
关键词:
HIV-1拮抗剂非肽类小分子化合物
Keywords:
HIV-1antagonistnon-peptide small molecular compounds
分类号:
O629
文献标志码:
A
摘要:
趋化因子受体 CCR5是 HIV-1病毒进入人体细胞的主要辅助受体,CCR5拮抗剂可作为一种靶向制剂,以防治人类 HIV-1感染。目前,非肽类小分子化合物 CCR5拮抗剂的研究占据主导地位。以4-氯苄氯、5-溴水杨醛为原料,通过消去、还原及溴化合成了4-溴-2-溴甲基-1-((4-溴苄基)氧)苯(中间体3),以哌啶-4-酮合成了 N-烯丙基-N-(4-哌啶基)吡啶甲酰胺(中间体7),通过中间体3和7合成了一种有望用作 CCR5拮抗剂的非肽类小分子化合物 N-烯丙基-N-(1-(5-溴-2-((4-氯苄基)氧基)苄基)-4-哌啶基)吡啶甲酰胺,该产物有一定的生物活性,并对该产物进行了1 H NMR、13 C NMR、IR 及 MS 表征。
Abstract:
Chemokine receptor CCR5 is a major coreceptor for HIV-1 entry into cell,CCR5 antagonists can be used as a targeting preparation in the prevention of human HIV-1 infection. At present,the peptide of small molecule compounds CCR5 antagonists research occupy the leading position. 4-bromo-2-(bromomethyl)-1-((4-chlorobenzyl) oxy)benzene( intermediate 3)was synthesized from 1-chloro-4-( chloromethyl)benzene and 5-bromo-2-hydroxy-benzaldehyde by elimination reaction,reduction reaction and bromization. N-allyl-N-( piperidin-4-yl)picolinamide (intermediate 7)was prepared from piperidin-4-one. Further reaction of intermediate 3 with intermediate 7 gave a novel non-peptide CCR5 antagonist N-allyl-N-(1-(5-bromo-2-((4-chlorobenzyl)oxy)benzyl)piperidin-4-yl)picoli-namide. The product has a certain biological activity,the compounds were characterized by 1 H NMR,13 C NMR,IR and MS.

参考文献/References:

[1] 焦诗卉,何淼.HIV辅助受体CCR5常见小分子抑制剂抑制效果的综合评价 [J].中山大学学报:自然科学版,2012,51(6):97-102.
[2] Mohsen Shahaei,Alireza Pourhossein.Modeling of CCR5 antagonists as anti HIV agents using combined genetic algorithm and adaptive neuro-fuzzy inference system(GA-ANFIS)[J].Med Chem Res,2013,22(9):4423-4436.
[3] Mohammed Abdul Rasheed,Nagul Meera Shaik,Nirogl R.Concise and aimple synthesis of M1 allosteric agonist TBPB [J].Synthetic Communications,2013,43(13):1796-1801.
[4] Ji Yongjun,Shu Mao,Lin Yong,et al.Combined 3D-QSAR modeling and molecular docking study on azacycles CCR5 antagonists [J].Journal of Molecular Structure,2013,1045(3):35-41.
[5] Renato Skerlj,Gary Bridger,Zhou Yuanxi,et al.Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic(R5)HIV-1 replication [J].Bioorganic & Medicinal Chemistry Letters,2011,21(23):6950-6954.
[6] Lavina Gharu,Rajesh Ringe,Jayanta Bhattacharya.HIV-1 clade C envelopes obtained from late stage symptomatic Indian patients varied in their ability towards relative CD4 usages and sensitivity to CCR5 antagonist TAK-779 [J].Virus Research,2011,158(1):216-224.
[7] Lu Shoufu,Chen Binglong,Dave Davey,et al.CCR5 receptor antagonists:Discovery and SAR of novel 4-hydroxypiperidine derivatives [J].Bioorganic & Medicinal Chemistry Letters,2007,17(7):1883-1887.
[8] Richard R G,John F W W,Brown K,et al.1,3-dihydro-2,1,3-benzothiadiazol-2,2-diones and 3,4-dihydro-1H-2,1,3-benzothidiazin-2,2-diones as ligands for the NOP receptor [J].Bioorganic & Medicinal Chemistry Letters,2004,14(20):5045-5050.
[9] Paul E F,Bryan O,Sander G M.Antagonists of the human CCR5 receptor as anti-HIV-1 agents.Part 4:Synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes [J].Bioorganic & Medicinal Chemistry Letters,2001,11(18):2475-2479.
[10] Christopher K A,Saheem A Z,Zhang Zhu,et al.Design syntheses,and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents [J].European Journal of Medicinal Chemistry,2013,69:647-658.
[11] Mark A Ashwell,Jean-Marc Lapierre,Alan Kaplan.The design preparation and SAR of novel small molecule sodium(Na)channel blockers [J].Bioorganic & Medicinal Chemistry Letters,2004,14(9):2025-2030.
[12] 王涛,黄海金,罗劲,等.2E-3-苯基丙烯酰氧基烃基膦酸二乙酯的合成与生物活性研究 [J].江西师范大学学报:自然科学版,2011,35(1):15-17.
[13] 汪淼.CCR5受体拮抗剂的设计、合成与生物活性研究 [D].沈阳:沈阳药科大学,2009.

备注/Memo

备注/Memo:
国家自然科学基金(51303115)
更新日期/Last Update: 1900-01-01